London
· Delayed Price · Currency is GBP · Price in DKK H. Lundbeck Company Description
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression.
It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis.
In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology.
The company was founded in 1915 and is headquartered in Valby, Denmark.
| Country | Denmark |
| Founded | 1915 |
| Industry | Pharmaceutical Preparations |
| Employees | 5,707 |
| CEO | Charl van Zyl |
Contact Details
Address: Ottiliavej 9 Valby, 2500 Denmark | |
| Phone | 45 36 30 13 11 |
| Website | lundbeck.com |
Stock Details
| Ticker Symbol | 0ND5 |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0010287234 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Charl van Zyl | Chief Executive Officer |
| Joerg Hornstein | Chief Financial Officer |
| Jens Hoyer | Head of Investor Relations |